Predictors of diabetic ketoacidosis in patients with insulin‐deficient diabetes phenotype initiating SGLT2 inhibitors
Diabetes, Obesity and Metabolism · 2025-09 · 27 (9) · 4989-4997
DOI: 10.1111/dom.16545 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 19.06.2025. Verfasst von Anat Tsur und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Clalit Health Services, Jerusalem, Israel. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetic Ketoacidosis, Diabetes Mellitus, Type 2, Insulin. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
To identify predictors of diabetic ketoacidosis (DKA) in patients with an insulin‐deficient phenotype initiating sodium‐glucose cotransporter 2 inhibitor (SGLT2i) therapy. Materials and Methods This retrospective cohort study analysed data from 31 900 patients with diabetes aged 18–70 identified as having an insulin‐deficient phenotype. After applying inclusion and exclusion criteria, patients were matched and divided into SGLT2i users ( n = 6572) and non‐users ( n = 6382). The primary endpoint was the first DKA event in patients with no prior history of DKA. Independent risk factors for DKA were assessed using Cox regression.
Results
Over a median follow‐up of 4.4 years, 239 patients experienced DKA (143 [2.22%] SGLT2i users vs. 96 [1.54%] non‐users; HR [95% confidence interval, CI] 1.39 [1.07–1.79]; p = 0.014). The adjusted model confirmed an increased DKA risk with SGLT2i use (adjusted hazard ratio, aHR [95% CI] 1.50 [1.15–1.95]; p = 0.003). Baseline HbA1c >9% was associated with a 53% higher risk (aHR [95% CI] 1.53 [1.18–1.99]; p = 0.0016), while body mass index (BMI) ≤25 kg/m 2 was linked to a 61% increased risk (aHR [95% CI] 1.61 [1.24–2.09]; p = 0.0003). Insulin use further heightened risk (aHR [95% CI] 2.35 [1.71–3.23]; p < 0.0001).
Conclusions
SGLT2i use in patients with an insulin‐deficient phenotype is associated with increased DKA risk, particularly in those with HbA1c >9% and BMI ≤25 kg/m 2 . Clinicians should exercise caution in these patients, carefully assessing risks and implementing mitigation strategies to ensure safe use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, Clalit Health Services, Jerusalem, Israel.
- The Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
- Department of Endocrinology and Metabolism, Hadassah Medical Center, Jerusalem, Israel.
- Clalit Health Services, Jerusalem, Israel.
ORCID-Profile: Anat Tsur, Avivit Cahn
Zitieren
APA
Tsur, A., Leibowitz, G., Cohen, M. J., Cahn, A., & Pollack, R. (2025). Predictors of diabetic ketoacidosis in patients with insulin‐deficient diabetes phenotype initiating SGLT2 inhibitors. Diabetes, Obesity and Metabolism, 27(9), 4989-4997. https://doi.org/10.1111/dom.16545
Vancouver
Tsur A, Leibowitz G, Cohen MJ, Cahn A, Pollack R. Predictors of diabetic ketoacidosis in patients with insulin‐deficient diabetes phenotype initiating SGLT2 inhibitors. Diabetes, Obesity and Metabolism. 2025;27(9):4989-4997. doi:10.1111/dom.16545
BibTeX
@article{Tsur2025,
author = {Tsur, Anat and Leibowitz, Gil and Cohen, Matan J and Cahn, Avivit and Pollack, Rena},
title = {Predictors of diabetic ketoacidosis in patients with insulin‐deficient diabetes phenotype initiating SGLT2 inhibitors},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
volume = {27},
number = {9},
pages = {4989--4997},
doi = {10.1111/dom.16545}
}
EUVIMED